secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-08-22T23:59:59+00:00
Accession:  0000950170-23-043808
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health implements 1-for-100 reverse stock split to avoid Nasdaq delisting
-------------------------------------------------------------------------------

- 1-for-100 reverse stock split effective Aug 23, 2023; par value unchanged.
- Nasdaq had determined to delist TIVC due to bid price ≤ $0.10 for 10 days; appeal hearing set Sep 21, 2023.
- Company expects reverse split to bring bid price above $1.00 and regain compliance.
- No fractional shares issued; fractional shares rounded up; percentage ownership unchanged.
- Warrants, options, and equity awards proportionally adjusted; CUSIP changes to 888705 209.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023043808/0000950170-23-043808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023043808/tivc-20230821.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-043808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer